CAS 1051375-10-0|Cabotegravir

Introduction：Basic information about CAS 1051375-10-0|Cabotegravir, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Cabotegravir BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Cabotegravir
CAS Number	1051375-10-0	Molecular Weight	405.352
Density	1.6±0.1 g/cm3	Boiling Point	664.0±55.0 °C at 760 mmHg
Molecular Formula	C₁₉H₁₇F₂N₃O₅	Melting Point	/
MSDS	/	Flash Point	355.4±31.5 °C

Names

Name	SureCN82803
Synonym	More Synonyms

Cabotegravir BiologicalActivity

Description	Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. Cabotegravir is an inhibitor of OAT1 (IC50 0.81 μM) and OAT3 (IC50 0.41 μM).IC50 value: 0.81 μM (OAT1), 0.41 μM (OAT3) [1]Target: OAT1, OAT3Cabotegravir is a potent HIV integrase inhibitor in clinical development as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.[2] Cabotegravir is an HIV-1 integrase inhibitor under development as a tablet for both oral lead-in therapy and long-acting (LA) injectable for intramuscular dosing.[3]
Related Catalog	Signaling Pathways >>Metabolic Enzyme/Protease >>HIV IntegraseSignaling Pathways >>Anti-infection >>HIVResearch Areas >>Infection
References	[1]. Reese MJ, Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12. [2]. Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12. [3]. Bowers GD, Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2015 Jul 1:1-16.

Description

Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. Cabotegravir is an inhibitor of OAT1 (IC50 0.81 μM) and OAT3 (IC50 0.41 μM).IC50 value: 0.81 μM (OAT1), 0.41 μM (OAT3) [1]Target: OAT1, OAT3Cabotegravir is a potent HIV integrase inhibitor in clinical development as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.[2] Cabotegravir is an HIV-1 integrase inhibitor under development as a tablet for both oral lead-in therapy and long-acting (LA) injectable for intramuscular dosing.[3]

Related Catalog

Signaling Pathways >>Metabolic Enzyme/Protease >>HIV IntegraseSignaling Pathways >>Anti-infection >>HIVResearch Areas >>Infection

References

[1]. Reese MJ, Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12.

[2]. Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12.

[3]. Bowers GD, Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2015 Jul 1:1-16.

Chemical & Physical Properties

Density	1.6±0.1 g/cm3
Boiling Point	664.0±55.0 °C at 760 mmHg
Molecular Formula	C₁₉H₁₇F₂N₃O₅
Molecular Weight	405.352
Flash Point	355.4±31.5 °C
Exact Mass	405.113617
PSA	104.36000
LogP	-1.70
Vapour Pressure	0.0±2.1 mmHg at 25°C
Index of Refraction	1.661
InChIKey	WCWSTNLSLKSJPK-LKFCYVNXSA-N
SMILES	CC1COC2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
Storage condition	-20℃

Synonyms

(3S,11aR)-N-(2,4-Difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide

Cabotegravir

Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-

GSK1265744A

unii-hmh0132z1q

Recommended......